13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001617201
Total reported value
$580.4M
$580.4M
46 檔
21.3%
During the Q2 2024 filing period, Prosight Management, LP (CIK: 0001617201) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $580.4M across 46 reported positions.
During Q2 2024, Prosight Management, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 10.00% | +2.93% | +44.92% | |
| 2 | ✓ | Adc Therapeutics SA | Stock-Other | 9.04% | -3.66% | +35.74% | |
| 3 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 6.32% | -0.82% | EXIT | |
| 4 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 6.06% | — | +35.70% | |
| 5 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 5.51% | — | +799.09% | |
| 6 | MGTX | MeiraGTx Holdings plc | Stock-Other | 5.48% | -3.52% | +8.35% | |
| 7 | STTK | Shattuck Labs Inc | Stock-Other | 5.39% | +1.84% | +25.37% | |
| 8 | KURA | Kura Oncology Inc | Stock-Other | 3.88% | -0.66% | -34.39% | |
| 9 | CYTK | Cytokinetics Inc | Stock-Healthcare | 3.72% | — | -6.12% | |
| 10 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.38% | +1.57% | — | |
| 11 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 3.22% | — | -32.30% | |
| 12 | KELYA | Kelly Services Inc -a | Stock-Other | 3.15% | — | +41.20% | |
| 13 | ZYME | Zymeworks Inc | Stock-Other | 3.00% | +0.83% | +187.14% | |
| 14 | IMVT | Immunovant Inc | Stock-Other | 2.56% | -0.72% | EXIT | |
| 15 | SDGR | Schrodinger Inc | Stock-Other | 2.13% | -0.95% | EXIT | |
| 16 | ABCL | Abcellera Biologics Inc | Stock-Other | 2.08% | — | +31.43% | |
| 17 | ALKS | Alkermes plc | Stock-Healthcare | 1.98% | +0.58% | +27.91% | |
| 18 | ERAS | Erasca Inc | Stock-Other | 1.94% | — | -24.86% | |
| 19 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.82% | -0.24% | EXIT | |
| 20 | PRTA | Prothena Corporation plc | Stock-Other | 1.77% | — | +68.32% | |
| 21 | KIDS | Orthopediatrics CORP | Stock-Other | 1.72% | -0.27% | -52.13% | |
| 22 | OPCH | Option Care Health Inc | Stock-Healthcare | 1.70% | +0.98% | NEW | |
| 23 | DXCM | Dexcom Inc | Stock-Healthcare | 1.67% | — | +114.42% | |
| 24 | ACCDUSD | Accolade Inc | Stock-Other | 1.59% | — | — | |
| 25 | COGT | Cogent Biosciences Inc | Stock-Other | 1.26% | — | -9.99% | |
| 26 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.11% | — | -11.48% | |
| 27 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.75% | — | -14.44% | |
| 28 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.74% | — | -71.52% | |
| 29 | CVS | Cvs Health CORP | Stock-Healthcare | 0.71% | — | — | |
| 30 | MDT | Medtronic plc | Stock-Healthcare | 0.71% | — | -83.33% | |
| 31 | ✓ | Vincerx Pharma Inc | Stock-Other | 0.60% | — | — | |
| 32 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 0.56% | — | — | |
| 33 | FNAUSD | Paragon 28 Inc | Stock-Other | 0.53% | — | — | |
| 34 | UHS | Universal Health Services-b | Stock-Healthcare | 0.52% | — | -68.76% | |
| 35 | PRVA | Privia Health Group Inc | Stock-Other | 0.50% | — | +113.48% | |
| 36 | ✓ | Mural Oncology Pub LTD Co | Stock-Other | 0.45% | — | +18.86% | |
| 37 | ADUS | Addus Homecare CORP | Stock-Other | 0.43% | — | — | |
| 38 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.33% | -0.16% | — | |
| 39 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.31% | — | -8.40% | |
| 40 | TXG | 10x Genomics Inc-class A | Stock-Other | 0.28% | — | +63.40% | |
| 41 | OVID | Ovid Therapeutics Inc | Stock-Other | 0.25% | — | +9.34% | |
| 42 | IMNM | Immunome Inc | Stock-Other | 0.24% | — | — | |
| 43 | RNTX | Rein Therapeutics Inc | Stock-Other | 0.22% | +0.11% | — | |
| 44 | IMRX | Immuneering CORP - Class A | Stock-Other | 0.21% | -0.08% | — | |
| 45 | BMEA | Biomea Fusion Inc | Stock-Other | 0.17% | — | +65.84% | |
| 46 | ✓ | Stock-Other | 0.01% | — | -94.18% |
According to official SEC Form 13F filings, Prosight Management, LP reported a total U.S. public equity portfolio value of $580.4M across 46 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LKFT, ADC THERAPEUTICS SA, ROIV) accounted for 21.3% of total reported equity market value during Q2 2024.
During Q2 2024, Prosight Management, LP's top holdings by market value included LKFT (10.0%)、ADC THERAPEUTICS SA (9.0%)、ROIV (6.3%). The largest single position, LKFT, represented 10.0% of total portfolio value.
In Q2 2024, Prosight Management, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.